EGFR and neoplasm: Gefitinib (4-(3-chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline (ZD1839)), a specific EGFR-TK inhibitor, is currently in clinical testing for various tumour entities (Baselga et al, 2002; Herbst, 2002).